FDA Grants Rare Pediatric Disease Designation to Vanda’s Investigational Therapy VCA-894A for Ultra-Rare CMT2S
The designation makes Vanda eligible for a Priority Review Voucher upon approval.
/ 220 items
#andre↓
Annovis Bio Gets Bullish Coverage from Roth Capital Amid Phase 3 Momentum
Annovis Bio receives bullish coverage from Roth Capital as its Phase 3 Alzheimer’s trial hits full enrollment.
Rodman & Renshaw Highlights (Z)-Endoxifen Potential as It Initiates Buy on Atossa Therapeutics
Rodman & Renshaw assigns Buy rating and $12 PT on (Z)-endoxifen, highlighting breast cancer program and rare disease upside.
Meta Stock Climbs as Muse Image Takes On OpenAI and Midjourney
Meta unveils Muse Image, its first in-house AI image generation model, integrated into Instagram, WhatsApp, and Meta AI.
Accenture Shares Surge as Accenture Edge AI Unit Launches with Google Cloud
Accenture stock rises after launching AI solutions with Google Cloud, boosting hopes for faster AI growth despite recent market challenges.
Agios Wins FDA Priority Review for First Oral PK Activator in Sickle Cell Disease
PDUFA target date is November 1, 2026. If approved, it would be the first oral PK activator for SCD patients.